is indicated for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history. It can also replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Genvoya.

Manufactured by: Gilead Sciences, Inc

Active Ingredient(s): Cobicistat; Elvitegravir; Emtricitabine; Tenofoviralafenamide fumarate

Dosage Form: Tablet, oral

Strength:  150 mg of Elvitegravir, 150 mg of Cobicistat, 200 mg of Emtricitabine, and 10 mg of Tenofovir Alafenamide Fumarate.

FDA approved: November 5, 2015

More information about Genvoya:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207561s000lbl.pdf

www.gilead.com/~/media/files/pdfs/medicines/hiv/genvoya/genvoya_pi.pdf